Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Clinical Management of Corneal Diseases
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Management of Corneal Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 18 April 2026 | Viewed by 2293

Special Issue Editor

Dr. Hyeck Soo Son

E-Mail Website
Guest Editor
Department of Ophthalmology, David J. Apple International Laboratory for Ocular Pathology and International Vision Correction Research Centre (IVCRC), University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Interests: corneal disease; corneal dystrophy; keratoplasty; keratoconus; corneal crosslinking

Special Issue Information

Dear Colleagues,

We are pleased to announce a new Special Issue entitled “Clinical Management of Corneal Diseases”, aimed at highlighting the rapid advancements and evolving practices in the diagnosis and treatment of corneal disorders. In recent decades, there has been an explosion of innovative treatment modalities, driven by remarkable technological advancements and improved diagnostic tools, revolutionizing the way clinicians manage a wide range of corneal conditions. This Special Issue welcomes the submission of original research articles and reviews that address various aspects of corneal care, including corneal transplantation, endothelial keratoplasty techniques such as DMEK and DSAEK, keratoprosthesis, surgical innovations such as intracorneal ring segments (ICRS, CAIRS) and Bowman layer transplantation, and diverse corneal crosslinking protocols, which continue to refine and expand the treatment of keratoconus and other ectatic disorders. We also encourage submissions that focus on treatment outcomes, clinical decision-making, and evidence-based management strategies. By presenting recent research and clinical experiences, this Special Issue aims to contribute to advancing the practice of corneal disease management worldwide.

Dr. Hyeck Soo Son
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • corneal diseases
  • keratoconus
  • corneal dystrophy
  • corneal ectasia
  • corneal transplantation
  • DMEK
  • DSAEK
  • kerato-prosthesis
  • crosslinking
  • ICRS
  • CAIRS
  • Bowman layer transplantation
  • treatment outcomes
  • clinical management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 3275 KB  
Article
Evaluation of the Effects of Eye Drops for Dry Eyes on Neuronal Pain Receptors in a Primary Culture Model of Trigeminal Ganglion Cells
by Chihiro Sunouchi, Takahiko Hayashi, Satoru Yamagami and Tohru Sakimoto
J. Clin. Med. 2025, 14(22), 8038; https://doi.org/10.3390/jcm14228038 - 13 Nov 2025
Viewed by 295
Abstract
Background: Dry eye disease is a multifactorial ocular surface disorder characterized by tear film instability, inflammation, and neurosensory abnormalities that can lead to corneal pain and discomfort. In this study, we evaluated the effects of specific eye drops for dry eyes on neuronal [...] Read more.
Background: Dry eye disease is a multifactorial ocular surface disorder characterized by tear film instability, inflammation, and neurosensory abnormalities that can lead to corneal pain and discomfort. In this study, we evaluated the effects of specific eye drops for dry eyes on neuronal pain receptors to gain insight into the mechanisms underlying corneal nerve pain in patients with dry eyes using a primary cell culture model of murine trigeminal ganglion cells. Methods: Trigeminal ganglia were obtained from wild-type postnatal day 7–10 mice. Primary cultures were prepared using the cell suspension method. After culturing for one week, the cells were stained with neuron-specific anti-neuronal nuclei, polymodal nociceptor, and transient receptor potential vanilloid 1 (TRPV1) antibodies. The calcium ion probe Fura2-AM® was added to cultured cells after 2 weeks of incubation. The effects of capsaicin alone, in combination with the TRPV1 antagonist AMG9810, and in the presence of components of commercially available eye drops (cyclosporine, diquafosol tetrasodium, or rebamipide) were evaluated by monitoring calcium signals. Results: Neural excitation and capsaicin-induced increase in fluorescence intensity ratio were suppressed by AMG9810, cyclosporine, and diquafosol tetrasodium, but not by rebamipide. Conclusions: Inhibition of cellular excitation by cyclosporine and diquafosol tetrasodium may underlie their clinical pain suppressive effects. The primary culture model described here may serve as a useful tool for future studies on corneal perception. Full article
(This article belongs to the Special Issue Clinical Management of Corneal Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 291 KB  
Review
Advancements and Innovations in Keratoconus Management: A Review of Current Practices
by Hyeck-Soo Son, Maximilian Friedrich, Albert S. Jun and Uri S. Soiberman
J. Clin. Med. 2025, 14(21), 7491; https://doi.org/10.3390/jcm14217491 - 23 Oct 2025
Viewed by 1829
Abstract
Keratoconus is a potentially blinding condition characterized by progressive thinning and steepening of the cornea, leading to visual impairment due to irregular astigmatism and myopia. While the exact pathophysiology is still unknown, it is believed to involve genetic, environmental, and cellular factors. Treatment [...] Read more.
Keratoconus is a potentially blinding condition characterized by progressive thinning and steepening of the cornea, leading to visual impairment due to irregular astigmatism and myopia. While the exact pathophysiology is still unknown, it is believed to involve genetic, environmental, and cellular factors. Treatment options for keratoconus have significantly expanded over the past few decades. Historically, glasses were the primary means of managing mild cases, whereas rigid gas permeable contact lenses were used in moderate to advanced diseases; yet the latter were rarely tolerated by patients with steep cones, in which full-thickness corneal transplantation was often performed. However, a variety of innovative treatments have been introduced in the past decades. Corneal collagen cross-linking (CXL) has revolutionized the field by halting the progression of keratoconus through creating new covalent bonds between individual corneal fibers. Custom, soft, and scleral contact lenses have improved visual outcomes for many patients. Additionally, surgical interventions such as intrastromal ring segments and Bowman layer transplantation have provided alternatives for visual restoration and postponing a potential keratoplasty. Furthermore, innovative cellular and pharmacological KCN treatments are on the horizon, awaiting clinical trials. This review article aims to provide a comprehensive overview of the current treatment options for keratoconus. Full article
(This article belongs to the Special Issue Clinical Management of Corneal Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop